The Society of Chemical Manufacturers and Affiliates (SOCMA) issued its support this week of the passage of pending free-trade agreements (FTA) with South Korea, Panama and Colombia by two Congressional committees. SOCMA is the US-based trade association representing custom and batch manufacturers, including contract manufacturers of fine chemicals, pharmaceutical intermediates, and active pharmaceutical ingredients.
Conflict between European and Indian pharma industries might be played out again in FTAs with other nations
While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over.
Pharmaceuticals might not have been the most discussed sector before the Korea-European Union Free Trade Agreement came into effect from July 1.
Millions of people dependent on life-saving generic drugs to treat HIV/AIDS will die if India stops producing cheap drugs for the disease due to its trade deal with the European Union, the head of UNAIDS warned on Tuesday.
This morning, in a small town in the region of Gent, Belgium, activists from Act Up-Paris woke up the European Commissioner for Trade in front of his house. They unfurled a banner which said ‘De Gucht, AIDS accomplice’.
One of WikiLeaks’ greatest achievements has been to expose the exorbitant amount of influence that multinational corporations have over Washington’s diplomacy.
The Asia Pacific Network of Positive People (APN+) is expressing outrage at ongoing free trade agreement negotiations by the United States with Vietnam and Malaysia that threaten access to medicines for HIV, TB, hepatitis-C as well as other diseases in these countries.
Statement of May 2011 against the increasingly rapid spread of Free Trade Agreements that put the profits of multinational pharmaceutical companies ahead of people’s right to health around the world.
India formally announced at the UN High
Level Meeting on HIV and AIDS that it will not accept data exclusivity, a
provision harmful to access to affordable medicines, as part of a free trade
agreement currently being negotiated with the European Union.
The TPP chapter may be best seen as a significant step toward the pharmaceutical industry’s ultimate goal, which is a binding international agreement on drug pricing that would restrain the ability of governments to use collective purchasing power to demand prices below “market” levels.
Pharmac is being targeted by US drug companies as trade negotiations continue with the United States.
As the global community meets in New York for the United Nations General Assembly High Level Meeting on HIV and AIDS from 8 to 10 June 2011, networks of People living with HIV, health groups and treatment activists from around the world are calling for an immediate moratorium on all Free Trade Agreements (FTAs) and TRIPS-plus measures.
Canadians spend a lot of money (public and private) on health care and much of that is spent on drugs — some $23.4 billion in 2008. Provincial insurance plans are desperately trying to cope, looking to initiatives like the recently passed Ontario law that caps prices of generic drugs at 25 per cent of the brand name equivalent.
Labour leader Phil Goff says his party would not put government drug buying agency Pharmac on the block to gain a free trade deal with the United States.
KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.
The Green Party is calling on the Government to take Pharmac off the table in Trans Tasman Partnership (TTP) negotiations.
Some of New Zealand’s most prominent businesspeople are rallying to the support of drug buying body Pharmac as lobbying firm Saunders Unsworth mounts a campaign against the agency ahead of free trade negotiations with the US.
US pharmaceutical industry association the Pharmaceutical Research and Manufacturers of America is calling on the US Trade Representative to include strong intellectual property provisions, such as 12-year data protection for follow-on biologics, in the Trans-Pacific Partnership agreement.
Nations currently negotiating trade deals with the European Union (EU) have been warned that they must resist European demands which could threaten access to medicines in emerging and developing countries.